Calliditas Therapeutics Ab (CALT) has released an update.
Calliditas Therapeutics AB celebrates FDA’s full approval of TARPEYO for IgA nephropathy, a landmark for patients with this rare kidney disease. The company’s financials show robust growth with net sales exceeding SEK 1.2 billion in 2023, underpinned by innovative treatments like TARPEYO and setanaxib, their NOX inhibitor platform’s lead compound. Calliditas’ commitment to addressing unmet medical needs is bolstered by their successful Phase 3 trial, global commercial partnerships, and expansion into new markets.
For further insights into CALT stock, check out TipRanks’ Stock Analysis page.
